SAVING OFFER*
†Treatment success=at least a 2-grade improvement in EGSS at Week 12.2
EGSS=Evaluator’s Global Severity Score.1,2
EGSS scale: 0 (clear); 1 (almost clear); 2 (mild); 3 (moderate); 4 (severe); 5 (very severe).1,2
0.0%(n=60)
vs vehicle 24.9%(n=55)P<0.001
0.0%(n=95)
vs vehicle 15.9%(n=79)P<0.001
0.0%(n=29)
vs vehicle 34.0%(n=43)P=0.020
0.0%(n=41)
vs vehicle 21.1%(n=45)P=0.001
Post hoc analysis of the results of a Phase 3, multicenter, randomized, double-blind, vehicle-controlled group study comparing the efficacy and safety of ONEXTON Gel once daily for 12 weeks with vehicle gel in patients 12 years and older with moderate to severe acne vulgaris (baseline 20-100 comedonal lesions).1,2
‡ ≥12 and <18
§ ≥25
0.0% (n=60)
vs vehicle 18.2% (n=55) P<0.001
0.0% (n=95)
vs vehicle 23.7% (n=79) P<0.001
0.0% (n=29)
vs vehicle 39.7% (n=43) P=0.019
0.0% (n=41)
vs vehicle 19.2% (n=45) P<0.001
Post hoc analysis of the results of a Phase 3, multicenter, randomized, double-blind, vehicle-controlled group study comparing the efficacy and safety of ONEXTON Gel once daily for 12 weeks with vehicle gel in patients 12 years and older with moderate to severe acne vulgaris (baseline 20-40 inflammatory lesions).1,2